Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Inventory Average (2017 - 2026)

Neurocrine Biosciences filings provide 9 years of Inventory Average readings, the most recent being $69.1 million for Q4 2025.

  • On a quarterly basis, Inventory Average rose 34.01% to $69.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $69.1 million, a 34.01% increase, with the full-year FY2025 number at $63.2 million, up 32.08% from a year prior.
  • Inventory Average hit $69.1 million in Q4 2025 for Neurocrine Biosciences, up from $63.1 million in the prior quarter.
  • In the past five years, Inventory Average ranged from a high of $69.1 million in Q4 2025 to a low of $26.9 million in Q3 2021.
  • Median Inventory Average over the past 5 years was $33.9 million (2023), compared with a mean of $39.7 million.
  • Biggest five-year swings in Inventory Average: fell 8.75% in 2023 and later skyrocketed 54.3% in 2025.
  • Neurocrine Biosciences' Inventory Average stood at $28.0 million in 2021, then increased by 28.75% to $36.0 million in 2022, then fell by 6.93% to $33.6 million in 2023, then soared by 53.8% to $51.6 million in 2024, then surged by 34.01% to $69.1 million in 2025.
  • The last three reported values for Inventory Average were $69.1 million (Q4 2025), $63.1 million (Q3 2025), and $58.0 million (Q2 2025) per Business Quant data.